Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer

Phase 2TerminatedNCT00924807

Beth Israel Medical Center4 enrolled

Overview

The purpose of this study is to evaluate the safety of a new drug- sorafenib, which is to be administered at the same time as standard treatment, which includes hormonal therapy and external beam radiotherapy.

Leuprolide acetate (a luteinizing hormone releasing hormone (LHRH) agonist) and Bicalutamide (an anti-androgen) are hormonal agents which are commonly used to reduce testosterone blood level for prostate cancer treatment. Intensity modulated external beam radiotherapy is a standard treatment for localized prostate cancer. Previous studies have shown that combining hormonal therapy and radiation is more effective than radiation alone. Unfortunately, significant percentages (50-75%) of patients still relapse. Sorafenib reduces the growth of cancer cells and has proven effective in the treatment of solid tumors including kidney and liver cancer. This drug is approved by the FDA for treatment kidney and liver cancer. The study investigators believe that adding sorafenib to standard treatment, comprising hormonal therapy and radiation, might be more effective then standard hormonal therapy.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Prostate Cancer

Interventions

Leuprolide acetate, Bicalutamide, SorafenibDRUG

Leuprolide acetate - depot, Bicalutamide 50 mg, Sorafenib 400mg

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients must have histologically confirmed intermediate or high risk prostate adenocarcinoma. Intermediate risk disease comprises T2b/c tumors, Gleason 7 histology, or PSA 10-20. High risk tumors comprise T3-4, Gleason 8 or higher histology, or PSA greater than 20. * Age \> 18 years. * Life expectancy of greater than 5 years. * Patients must have normal organ and marrow function. * No pelvic lymph node metastases based on pelvic CT scan or MRI. * No bone metastasis. A whole body bone scan is required to rule out metastatic disease. Exclusion Criteria: * Any previous, radiotherapy, or chemotherapy, or more than 4 weeks of androgen deprivation hormonal therapy for the treatment of prostate adenocarcinoma. * Patients may not be receiving any other investigational agents. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib or other agents used in this study. * Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C. * Patients receiving anti-coagulation treatment with an agent such as warfarin or heparin will not be allowed to participate.

Locations (1)

St.Luke's-Roosevelt Hospital Center

New York, New York, United States

Outcomes

Primary Outcomes

Determine the Safety and Maximally Tolerated Dose of Sorafenib Administered Concurrently With Radiotherapy in the Treatment of Intermediate- and High-risk Localized Prostate Cancer.

Data of zero ("0") participants were analyzed due to lack of funding and prematurely terminating the study by sponsor. All subjects are following up in the clinic off the study.

Time frame: Day 29 and every 2 weeks

Secondary Outcomes

Biochemical Disease-free Survival

Data of zero ("0") participants were analyzed due to lack of funding and prematurely terminating the study by sponsor. All subjects are following up in the clinic off the study.

Time frame: after 9 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.